Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Angiotensin-(1-7) reduces cardiac effects of thyroid hormone by GSK3Β/NFATc3 signaling pathway.

Senger N, Melo MB, Diniz GP, Campagnole-Santos MJ, Santos RAS, Barreto-Chaves MLM.

Clin Sci (Lond). 2018 Jun 5;132(11):1117-1133. doi: 10.1042/CS20171606. Print 2018 Jun 14.

PMID:
29685981
2.

Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3',5'-cyclic monophosphate-dependent pathway.

Gomes ER, Lara AA, Almeida PW, Guimarães D, Resende RR, Campagnole-Santos MJ, Bader M, Santos RA, Guatimosim S.

Hypertension. 2010 Jan;55(1):153-60. doi: 10.1161/HYPERTENSIONAHA.109.143255. Epub 2009 Dec 7.

PMID:
19996065
3.

Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3beta/mTOR signaling pathway.

Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML.

Basic Res Cardiol. 2009 Nov;104(6):653-67. doi: 10.1007/s00395-009-0043-1. Epub 2009 Jul 9.

PMID:
19588183
4.

Cardiac ACE2/angiotensin 1-7/Mas receptor axis is activated in thyroid hormone-induced cardiac hypertrophy.

Diniz GP, Senger N, Carneiro-Ramos MS, Santos RA, Barreto-Chaves ML.

Ther Adv Cardiovasc Dis. 2016 Aug;10(4):192-202. doi: 10.1177/1753944715623228. Epub 2015 Dec 28.

5.

Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling.

Santiago NM, Guimarães PS, Sirvente RA, Oliveira LA, Irigoyen MC, Santos RA, Campagnole-Santos MJ.

Hypertension. 2010 Apr;55(4):889-96. doi: 10.1161/HYPERTENSIONAHA.110.149815. Epub 2010 Mar 8.

PMID:
20212262
6.

Renin-angiotensin system contribution to cardiac hypertrophy in experimental hyperthyroidism: an echocardiographic study.

Basset A, Blanc J, Messas E, Hagège A, Elghozi JL.

J Cardiovasc Pharmacol. 2001 Feb;37(2):163-72.

PMID:
11209999
7.
8.

Cardiac-specific Traf2 overexpression enhances cardiac hypertrophy through activating AKT/GSK3β signaling.

Huang Y, Wu D, Zhang X, Jiang M, Hu C, Lin J, Tang J, Wu L.

Gene. 2014 Feb 25;536(2):225-31. doi: 10.1016/j.gene.2013.12.052. Epub 2013 Dec 27.

PMID:
24378234
9.

Local angiotensin II aggravates cardiac remodeling in hypertension.

Xu J, Carretero OA, Liao TD, Peng H, Shesely EG, Xu J, Liu TS, Yang JJ, Reudelhuber TL, Yang XP.

Am J Physiol Heart Circ Physiol. 2010 Nov;299(5):H1328-38. doi: 10.1152/ajpheart.00538.2010. Epub 2010 Sep 10.

10.

Angiotensin type 1 (AT1) and type 2 (AT2) receptors mediate the increase in TGF-beta1 in thyroid hormone-induced cardiac hypertrophy.

Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML.

Pflugers Arch. 2007 Apr;454(1):75-81. Epub 2007 Jan 6.

PMID:
17206447
11.

Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation.

Carneiro-Ramos MS, Diniz GP, Nadu AP, Almeida J, Vieira RL, Santos RA, Barreto-Chaves ML.

Basic Res Cardiol. 2010 May;105(3):325-35. doi: 10.1007/s00395-010-0089-0. Epub 2010 Feb 14.

PMID:
20155476
12.

Maternal hyperthyroidism alters the pattern of expression of cardiac renin-angiotensin system components in rat offspring.

Lino CA, Shibata CE, Barreto-Chaves ML.

J Renin Angiotensin Aldosterone Syst. 2014 Mar;15(1):52-60. doi: 10.1177/1470320312470581. Epub 2012 Dec 20.

PMID:
23257210
13.

[Contribution of the renin-angiotensin system to blood pressure variability in hyperthyroid rats].

Basset A, Blanc J, Elghozi JL.

Arch Mal Coeur Vaiss. 2000 Aug;93(8):905-10. French.

PMID:
10989728
14.

Activation of angiotensin II type 1 receptor-associated protein exerts an inhibitory effect on vascular hypertrophy and oxidative stress in angiotensin II-mediated hypertension.

Wakui H, Dejima T, Tamura K, Uneda K, Azuma K, Maeda A, Ohsawa M, Kanaoka T, Azushima K, Kobayashi R, Matsuda M, Yamashita A, Umemura S.

Cardiovasc Res. 2013 Dec 1;100(3):511-9. doi: 10.1093/cvr/cvt225. Epub 2013 Nov 4.

PMID:
24189624
15.

The renin-angiotensin system and experimental heart failure.

Wollert KC, Drexler H.

Cardiovasc Res. 1999 Sep;43(4):838-49. Review.

PMID:
10615411
16.

Cardiac microRNA-133 is down-regulated in thyroid hormone-mediated cardiac hypertrophy partially via Type 1 Angiotensin II receptor.

Diniz GP, Lino CA, Guedes EC, Moreira Ldo N, Barreto-Chaves ML.

Basic Res Cardiol. 2015 Sep;110(5):49. doi: 10.1007/s00395-015-0504-7. Epub 2015 Jul 23.

PMID:
26202011
17.

Angiotensin II type 1 receptor-associated protein prevents vascular smooth muscle cell senescence via inactivation of calcineurin/nuclear factor of activated T cells pathway.

Min LJ, Mogi M, Tamura K, Iwanami J, Sakata A, Fujita T, Tsukuda K, Jing F, Iwai M, Horiuchi M.

J Mol Cell Cardiol. 2009 Dec;47(6):798-809. doi: 10.1016/j.yjmcc.2009.09.006. Epub 2009 Sep 18.

PMID:
19769983
18.

Angiotensin II type 2 receptor (AT2R) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion.

Tavares FM, da Silva IB, Gomes DA, Barreto-Chaves ML.

Cardiovasc Drugs Ther. 2013 Oct;27(5):393-402. doi: 10.1007/s10557-013-6473-x.

PMID:
23807455
19.

Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.

Leenen FH, White R, Yuan B.

Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2410-6.

20.

Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats.

Wang H, Jessup JA, Zhao Z, Da Silva J, Lin M, MacNamara LM, Ahmad S, Chappell MC, Ferrario CM, Groban L.

PLoS One. 2013 Oct 25;8(10):e76992. doi: 10.1371/journal.pone.0076992. eCollection 2013.

Supplemental Content

Support Center